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Multiple sclerosis (MS) is a demyelinating disease that causes major neurological
disability in young adults. A definitive diagnosis at the time of the first episode is still
lacking, but since early treatment leads to better prognosis, the search for early biomarkers
is needed. Here we characterized the transcriptome of the choroid plexus (CP), which is
part of the blood-brain barriers (BBBs) and the major site of cerebrospinal fluid production,
in the experimental autoimmune encephalomyelitis (EAE) mousemodel of MS. In addition,
cerebrospinal fluid samples from two cohorts of patients with MS and with optic neuritis
(ON) were analyzed to confirm the clinical relevance of the findings. Genes encoding for
adhesion molecules, chemokines and cytokines displayed the most altered expression,
supporting the role of CP as a site of immune-brain interaction in MS. The gene encoding
for lipocalin 2 was the most up-regulated; notably, the cerebrospinal fluid lipocalin 2
levels coincided with the active phases of the disease. Immunostaining revealed that
neutrophils infiltrating the CP were the source of the increased lipocalin 2 expression
in this structure. However, within the brain, lipocalin 2 was also detected in astrocytes,
particularly in regions typically affected in patients with MS. The increase of lipocalin 2
in the cerebrospinal fluid and in astrocytes was reverted by natalizumab treatment. Most
importantly, the results obtained in the murine model were translatable into humans since
patients from two different cohorts presented increased cerebrospinal fluid lipocalin 2
levels. The findings support lipocalin 2 as a valuable molecule for the diagnostic/monitoring
panel of MS.
Keywords: multiple sclerosis, lipocalin 2, experimental autoimmune encephalomyelitis, astrocytes, cerebrospinal
fluid, natalizumab
INTRODUCTION
Multiple sclerosis (MS) is a chronic progressive inflammatory
disease of the central nervous system (CNS) characterized by
an immune response against the myelin sheath of CNS axons.
A notable aspect of the disease is the migration of inflamma-
tory cells through the brain barriers towards the CNS. These
cells, together with activated astrocytes and microglia, are likely
to induce the demyelination and neurodegeneration observed in
the MS lesions, ultimately resulting in the loss of motor func-
tions (Brown and Sawchenko, 2007; Vercellino et al., 2009). As
such, current clinical therapies are greatly directed at inhibiting
lymphocyte trafficking to the CNS (Hemmer et al., 2006).
The blood-brain barrier (BBB), formed by the endothelial cells
of brain capillaries, and the blood-cerebrospinal fluid (CSF) bar-
rier, formed by the choroid plexus (CP) epithelial cells, are the
main interfaces between the CNS and the periphery. In MS, it
appears that the first wave of CNS-infiltrating T cells, specifically
T helper 17 (Th17), enter through the CP; this primary event
triggers the entry of a second T cell wave that migrates in large
numbers through the BBB into the CNS (Reboldi et al., 2009).
In addition, the brain barriers are also of primary interest given
their secretome, which, via the CSF (mostly produced by the CP)
or by direct action on the brain parenchyma, may modulate brain
homeostasis (Zlokovic, 2008; Marques et al., 2009a). Findings
attesting the relevance of the CSF-CP in MS also include the
observation that most MS lesions localize in periventricular areas
and that the CSF composition may participate in disease develop-
ment, a contribution that remains poorly understood. The CSF
composition is reflective of brain metabolism, thus, CSF analysis
is a useful diagnostic tool for neurological diseases (Tumani et al.,
2009). The search for biomarkers that correlate with MS dis-
ease progression and activity is particularly needed given that
early treatment can lead to a more favorable prognosis (Comi
et al., 2000). To further understand whether the brain barrier at
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the CP contributes to MS, and to search for novel biomarkers,
we characterized here the CP transcriptome in the onset, remis-
sion and relapse phases of the murine experimental autoimmune
encephalomyelitis (EAE) model of MS. To verify if the findings
were of relevance to the human disease, we also assessed the CSF
composition from two distinct human cohorts of MS.
METHODS
ANIMALS AND INDUCTION OF EAE
All experiments were conducted using 6–8 weeks of age adult
female SJL mice (Charles River, Barcelona, Spain) in accordance
with the Portuguese national authority for animal experimenta-
tion, Direção Geral de Veterinária (ID: DGV9457). Animals were
kept and handled in accordance with the guidelines for the care
and handling of laboratory animals in the Directive 2010/63/EU
of the European Parliament and of the Council. The animals were
housed and maintained in a controlled environment at 22–24◦C
and 55% humidity, on 12 h light/dark cycles and fed with regu-
lar rodent’s chow and tap water ad libitum. Animals were handled
for 1 week prior to the beginning of the experiment, in order to
reduce the stress induced by the injections.
For the induction of the relapsing-remitting EAE model,
female SJL mice were subcutaneously injected in the hind flanks,
with 0.2mg of the encephalitogenic proteolipid protein (PLP)
139–151 peptide (HSLGKWLGHPDKF) (Primm,Milan, Italy), in
Complete Freund’s Adjuvant (CFA; Difco Laboratories, Detroit,
MI, USA), on days 0 and 7. Each mouse was also intraperitoneally
injected with 0.2μg of pertussis toxin (Sigma, St. Louis, MO,
USA) on days 0, 1, 7, and 8. Control mice were injected with phos-
phate buffer saline (PBS) in CFA and pertussis toxin, according to
the same schedule (Columba-Cabezas et al., 2006). All mice were
weighed and examined daily for the clinical signs of EAE, which
was scored according to the following scale: grade 0, no abnormal-
ity; grade 1, reduced tail tonus or slight clumsy gait; grade 2, tail
atony, moderately clumsy gait, impaired righting ability, or any
combination of these signs; grade 3, additional hind limb weak-
ness; grade 4, hind limb paralysis and fore limb weakness; grade 5,
tetraplegia or moribund state. Mice developed an acute form of
EAE with a peak between days 12 and 14 (grades 1–4), which was
termed onset. A phase of complete remission took place between
days 19 and 22, with some mice undergoing a relapse (grades 1
and 2) after a variable period of time (27–31 days).
HUMAN SAMPLES
For the human studies, CSF samples were obtained according to
standardized protocols and refer to patients admitted for lumbar
puncture in the Hospital de Braga, Portugal, and in the Glostrup
Hospital, Denmark, between February 2009 and September 2011.
Patients were referred to the Neuroimmunology Clinic, Hospital
de Braga, Portugal, or the Clinic of Optic Neuritis, Glostrup
Hospital, Denmark and underwent diagnostic program including
magnetic resonance imaging (MRI) scan and lumbar puncture.
Lumbar puncture was performed within 30 days of symptom
debut, thus in the active phase of disease. The groups included
in this study were controls, optic neuritis (ON) patients and
patients with clinically definite relapsing remitting MS. Controls
from Braga were individuals, of similar age and gender as cases
that were referred to the neurology department because of neu-
rological complaints, who were found to have no CNS disorder
and normal CSF examination; Glostrup controls were age and
gender matched, with no genetical disposition to autoimmune
disease and had a normal neurological examination. Selected ON
patients, all from Glostrup, were in the lower end of the risk to
develop MS, one ON patient had a single white matter lesion
and one had pathological CSF, the remaining had no pathological
finding in CSF and in the MRI. All MS patients, from both Braga
and Glostrup, were diagnosed according to the McDonald 2005
criteria (Polman et al., 2005); additionally, all except three had
pathological CSF with oligoclonal bands (OCB) or increased IgG-
index. The studies with human CSF were approved by the Danish
ethical committee and the ethical committee of Hospital de Braga
and all patients and controls signed an informed consent.
NATALIZUMAB TREATMENT
In the natalizumab treatment protocol, EAE was induced and
after appearance of the first clinical signs animals were injected
intraperitoneally with 5mg/Kg of anti-VLA-4 antibody (natal-
izumab) (Biogen Idec, Boston, MA, USA) or in the case of control
mice with rat IgG (Sigma). To better represent clinical use, treat-
ment injections were performed during the active phase (1, 3,
and 5 days after the appearance of the symptoms) (i.e., reverting
symptoms) (Theien et al., 2001). Animals were sacrificed at day
14 (that corresponds to the onset phase for animals not treated
with natalizumab).
TISSUE AND CSF COLLECTION
Mice were sacrificed during the first peak of disease (onset), dur-
ing the remission phase and in the relapse phase. Mice from
the control group were sacrificed on day 14, along with mice
from the onset group. Animals were anesthetized with ketamine
hydrochloride (150mg/Kg) plus medetomidine (0.3mg/Kg), CSF
samples were collected from the cisternamagna, and animals were
transcardially perfused with cold saline. CSF pooled samples were
checked for blood contamination and stored at –80◦C. After per-
fusion the CP’s were rapidly removed from each mouse ventricle
under conventional light microscopy (SZX7, Olympus, Hamburg,
Germany), frozen in dry ice and stored at –80◦C.
For the expression studies, two sets of animals from each
experimental group (control, onset, remission, and relapse)
were prepared: one for the microarray analysis containing 3
separate pooled CP samples for onset and remission phase and
2-pooled CP for the relapse phase (from three animals each)
and another to the quantitative Real Time-Polymerase Chain
Reaction (qRT-PCR) containing at least from 5 pools of CP
(from three animals each).
MICROARRAY EXPERIMENTAL DESIGN AND DATA ANALYSIS
Total RNA was isolated with Trizol (Invitrogen, Carlsbad,
CA, USA) following manufacturer’s instructions. After quality
assessment using the Agilent Bioanalyzer (Agilent Technologies,
CA, USA), 100 ng of total RNA were amplified and labeled
with Illumina TotalPrep RNA Amplification Kit (Illumina Inc.,
San Diego, CA, USA). The labeled cRNA was then hybridized
using the recommended protocol in a total of two Illumina
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Whole-genome Mouseref-8 expression Beadchips (Illumina
Inc., San Diego, CA, USA). This mouse beadchip contains
eight arrays, each comprising a total of 24,000 well-annotated
RefSeq transcripts. After scanning, raw data from BeadStudio
software (Illumina Inc., San Diego, CA, USA) was read into
R/Bioconductor and normalized using quantile normalization.
A linear model was applied to the normalized data using Limma
package in R/Bioconductor. A contrast analysis was applied and
differentially expressed genes were selected using a Bayesian
approach with a false discovery rate of 5%. All data is Minimum
Information About a Microarray Experiment (MIAME)-
compliant and the raw data has been deposited in the GEO
database. The differentially expressed genes were categorized
using Gene Ontology from Biomart (http://www.biomart.org/)
or Ingenuity tools (Redwood City, CA, USA). Enrichment
analysis was performed using the DAVID (http://david.niaid.nih.
gov/david/ease.htm) and the Ingenuity softwares.
GENE EXPRESSION MEASUREMENTS BY qRT-PCR
Total RNA was isolated from the CP as described before. An
amount of 500 ng of RNA from each pool was amplified using
a SuperScript RNA Amplification System (Invitrogen) according
to the manufacturer’s instructions. After amplification, RNA
was reverse transcribed into first strand cDNA using random
hexamers of the superscript first-strand synthesis system for
RT-PCR (Invitrogen). Primers used to measure the expression
levels of selected mRNA transcripts by qRT-PCR were designed
using the Primer3 software, on the basis of the respective
GenBank sequences. All accession numbers and primer sequences
are available on request. The reference gene for hypoxanthine
guanine phosphoribosyl transferase (Hprt) (accession number
from GenBank: NM_013556) was used as an internal stan-
dard for the normalization of the expression of selected tran-
scripts. qRT-PCR was performed on a CFX 96TM real time
system instrument (Bio-Rad Laboratories, Hercules, CA, USA),
with the QuantiTect SYBR Green RT-PCR reagent kit (Qiagen,
Hamburg, Germany) according to the manufacturer’s instruc-
tions, using equal amounts of RNA from each sample. Product
fluorescence was detected at the end of the elongation cycle.
All melting curves exhibited a single sharp peak at the expected
temperature.
IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE ANALYSES
Animals were transcardially perfused with saline, under anesthe-
sia, at the various time points mentioned before. After perfusion,
brains were removed from the skull, immediately embedded in
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FIGURE 1 | LCN2 is increased in EAE. (A) Immunization of SJL female mice
was performed on days 0 and 7. Animals were sacrificed at the different
phases of the disease and control animals at day 14. The CP transcriptome
from the onset, remission, and relapse phases were compared with the CP
transcriptome of non-induced animals. (B) Disease course of SJL mice
immunized with PLP/CFA emulsion. (C) Augmented levels of CSF LCN2
were observed in the EAE active phases: onset and relapse. (D)
Immunohistochemistry analysis showed that LCN2 staining is observed in
the CP stroma cells but not in the CP epithelial cells (panels a and b). Staining
for Ly6G identified neutrophils as the cells labeling for LCN2 in the CP stroma
(panel c–e). LV, lateral ventricle. Data represent mean ± SE. Scale bars,
50μm.
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Tissue-Tek optimal cutting temperature compound and kept
frozen at –20◦C. Brains were sectioned in serial 20μm cryostat
coronal sections, which were then fixed with 4% PFA in PBS.
After antigen retrieval with citrate buffer 10mM, the sections
were probed with the primary antibody, anti-mouse lipocalin-
2/neutrophil gelatinase-associated lipocalin (LCN2/NGAL)
(1:400; R&D Systems, MN, USA), diluted in PBS 0.3% Triton
X-100 (PBS-T), and 0.4% bovine serum albumin (Sigma).
Afterwards the sections, were incubated with biotinylated
anti-goat secondary antibody and then with streptavidin per-
oxidase conjugate (ABC kit; Sigma). Reaction was developed
with 3,3′-diaminobenzidine tetrahydrochloride hydrate (DAB;
Sigma) and sections stained with hematoxylin. Alternatively, for
immunofluorescent staining, sections were incubated with goat
anti-mouse LCN2/NGAL in conjunction with: rabbit anti-glial
fibrillary acidic protein (anti-GFAP) (1:200; Dako, Glostrup,
Denmark) to label astrocytes, rat anti-mouse Ly-6G to label
neutrophils (1:200; clone 1A8, BD Biosciences, Franklin Lakes,
NJ, USA), mouse anti-CNPase to label oligodendrocytes [1:100;
Chemicon (Millipore), Billerica, MA, USA], mouse anti-NeuN
(1:100; Millipore, Billerica, MA, USA) to label neurons and
rabbit anti-Iba1 (1:200; Wako chemicals, Richmond, VA, USA)
to label microglia. The appropriate secondary fluorescent anti-
bodies diluted 1:500 in PBS-T were used: anti-goat Alexa 488,
anti-rabbit and anti-mouse Alexa 594, anti-rat Alexa 547 (all
from Invitrogen). For each analysis, sections from 3–5 different
animals per group were used. The cell nucleus was stained using
4′, 6-diamidino-2-phenylindole (DAPI). Samples were analyzed
using optical (BX61; Olympus) or confocal (FV1000; Olympus)
microscopes.
LCN2 QUANTIFICATION IN MICE AND HUMAN CSF
LCN2 protein determination in the CSF was done by a direct
enzyme-linked immunosorbent assay, using 2μl of CSF for
mice and 5μl for humans. LCN2 was detected using the goat
anti-mouse LCN2/NGAL or anti-human LCN2/NGAL (both
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FIGURE 2 | Transcriptome signature of the EAE CP. (A) Number of
genes whose expression was found altered in the onset, remission,
and relapse phases. Up-regulated genes are in red and down-regulated
are in green. (B) Clustering of the genes whose expression was
altered in the CP upon EAE induction. The number of genes altered
in each pathway in the onset remission, and relapse phases are
represented in red, green and brown, respectively. Microarray data
are representative of one single experiment. For each time point at
least 2 pools of CP were analyzed and each pool contained CP’s from
three animals.
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from R&D Systems), at 1:300 dilution, followed by a sec-
ondary peroxidase-conjugated donkey anti-goat antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at 1:500 dilu-
tion, and developed with 2-2′azinobis (3-ethylbenzthiazoline-
6-sulphonic acid) diammonium salt (ABTS; Sigma). The reac-
tion was stopped using 0.1mol/L citric acid and read at an
optical density of 405 nm. The standard curves were made
with recombinant mouse LCN2/NGAL or recombinant human
LCN2/NGAL (both from R&D Systems). The detection limit
for the mice assay was 50 ng/mL and for the human was
0.5 ng/mL, being the linearity of the assay for the human
samples from 0.5–10ng/ml and for the mouse from 400–
800 ng/ml.
STATISTICAL ANALYSIS
Values are reported as mean ± SE. Statistical significance was
determined using the nonparametric Mann–Whitney U test,
and ANOVA analysis with differences considered significant at
p < 0.05 (∗) and p < 0.01 (∗∗), except for the proportion of
patients with LCN2 positive CSF which was analyzed with the
chi-square test.
RESULTS
EAE INDUCTION MODEL
The experimental timeline is diagramed in Figure 1A. Of the
animals injected with PLP peptide in CFA, 85–90% developed
an acute form of EAE (grade 3–4), which peaked around days
14–19 after immunization, and spontaneously resolved 5–6 days
after peaking (Figure 1B). The remission phase was followed by
a relapse phase (clinical grade 1–2) around days 29–30 after
immunization (Figure 1B).
THE CP TRANSCRIPTOME IS ALTERED DURING THE DIFFERENT
PHASES OF EAE
CP microarray analysis yielded several up- and down-regulated
genes: 633 and 290 genes in the onset, 484 and 180 in the
remission, and 309 and 96 in the relapse, respectively (Figure 2A).
Gene ontology and biological pathway analysis of differentially
expressed genes showed that the most altered biological path-
ways included chemokine signaling, focal adhesion, cell adhesion,
and leukocyte transendothelial migration (Figure 2B); and genes
of interest included selectins, chemokines and matrix metallo-
proteinases (raw data has been deposited in the GEO database,
accession: GSE35363). Attending to the fold change, Lcn2 was
the most significantly up-regulated gene in the onset phase of
EAE (3.1-fold change), with a reduction in expression during the
remission phase (although remaining marginally up-regulated—
1.33-fold change). The pattern of expression was confirmed by
qRT-PCR analysis (Figure 3).
LCN2 CSF LEVELS CORRELATE WITH THE EAE ACTIVE PHASES
We next quantified CSF LCN2 levels to determine if the
CP altered gene expression profile resulted in increased pro-
tein concentration in the CSF. Interestingly, CSF LCN2 lev-
els were comparably increased in both the EAE onset and
relapse phases, while normalized in the remission phase
(Figure 1C). The increased LCN2 CSF levels in the relapse
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FIGURE 3 | qRT-PCR for CP Lcn2. Lcn2 expression was strongly induced
during the onset phase of the disease returning to control levels in the
remission and relapse phases. Data are representative of one independent
experiment (at least 5 pools of CP, each containing CP’s from three
animals). Data represent mean ± SE.
phase contrasted with the lack of up-regulation in the CP
gene expression in that phase, suggesting that the CSF LCN2
originates from a source other than the CP. To elucidate the
LCN2 origin, immunohistochemical studies were conducted
(Figure 1D). No staining was observed for LCN2 in the CP
epithelial cells in any phase of the disease but rather in the
CP stroma in the onset phase (Figure 1D, panels a and b).
Staining in stroma was localized and restricted to infiltrat-
ing neutrophils (double staining with neutrophil marker Ly6G;
Figure 1D, panels c–e).
A DUAL SOURCE OF LCN2 IN THE BRAIN PARENCHYMA
To further investigate possible sources for the LCN2 present in
the CSF, whole brain parenchyma immunohistochemical analysis
was performed. In the onset phase, LCN2 staining was observed in
the olfactory bulb, periventricular regions surrounding the lateral
and 3rd ventricles, cerebellum, and brain stem (Figure 4). In con-
trast, in the relapse phase, the cerebellum and the brain stem were
the most highly stained regions. Double immunofluorescence
studies using markers for oligodendrocytes (CNPase), microglia
(Iba1), neurons (NeuN) and astrocytes (GFAP), indicated that,
apart from infiltrating neutrophils, the only cells producing LCN2
were astrocytes (Figure 5A). Of notice, LCN2 expression by neu-
trophils and astrocytes was only observed in the onset and relapse
phases (Figure 5A, panels d–f and j–l), in accordance with CSF
protein levels (Figure 1C).
Given that in MS patients the cerebellum is commonly affected
(Calabrese et al., 2010), we further analyzed the astrocytic LCN2
regional expression in this structure. LCN2 was mainly expressed
in the white matter and in the granular layer with no cells found
in the molecular layer (Figure 5A). Quantitatively, the number of
stained cells was higher in the onset than in the relapse phase of
EAE (Figure 5B), which correlated with the animals’ clinical score
(Figure 1B).
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FIGURE 4 | Schematic representation of the LCN2 expression
distribution in the EAE brains. Staining was mostly observed in the
olfactory bulb, periventricular regions surrounding the lateral and 3rd
ventricles, cerebellum and brain stem in the active phases of EAE. The
cerebellum and the brain stem were the regions more highly stained in the
relapse phase. No DAB-positive staining was observed in the brain
parenchyma of control animals or in the remission phase of the disease.
+ + +, high expression; + +, medium expression; +, low expression. Data
are representative of two independent experiments each containing four
animals/group.
NATALIZUMAB TREATMENT MODULATES LCN2 EXPRESSION
Natalizumab, one of the most effective MS treatments, is a
humanized mouse monoclonal antibody against the integrin very
late activation (VLA)-4 on leukocytes (Iaffaldano et al., 2011)
that blocks leukocyte entry into the CNS. Natalizumab treat-
ment (Figure 6A) ameliorated the clinical manifestations of the
disease (clinical score 0.5, Figure 6B) and significantly decreased
LCN2 CSF levels (Figure 6C); which corresponded to an abro-
gated expression of LCN2 in astrocytes (Figures 6D,E) and to a
reduction of neutrophils infiltrating the brain parenchyma (data
not shown), when compared to IgG-treated animals.
LCN2 IS INCREASED IN CSF SAMPLES FROM MS PATIENTS
To investigate whether the findings in the murine EAE model
were also observed in humans, LCN2 CSF levels were analysed
in two separate MS cohorts. Samples were divided in three clin-
ical groups: controls (age and gender matched), patients with
monosymptomatic ON and patients with clinically active MS.
LCN2 was detected in 5/20 (25%) control samples, in 1/9 (11%)
ON, and in 12/20 (60%) MS samples [χ2
(df= 5) = 13.98; p =
0.0158). Additionally, CSF LCN2 levels were significantly higher
in MS patients when compared to controls and ON patients
(Figure 6F).
DISCUSSION
Here we identify LCN2 as a novel protein whose presence in
the CSF and expression in the brain parenchyma (astrocytes and
infiltrating neutrophils) correlates with the active phases of the
EAE mice model and is reverted to normal levels with natal-
izumab treatment. Additionally, LCN2 CSF levels were found
significantly higher in MS patients when compared to healthy
individuals or ON patients. These observations suggest that LCN2
CSF levels may be of relevance to include in the panel of MS CSF
markers. In addition, we describe the CP transcriptome in the
onset, relapse, and remission phases of EAE. Of notice, the most
altered biological pathways were associated with leukocyte migra-
tion to the CNS, supporting the CP as a possible route of initial
leucocytes entry into the brain (Vercellino et al., 2008; Reboldi
et al., 2009). Several additional pathways were found altered and
should be further investigated in order to understand whether
specific modulators of disease onset and progression are present
at the BBBs.
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FIGURE 5 | LCN2 is produced by astrocytes. (A) Double
immunofluorescence labeling for LCN2 (green) and of GFAP for astrocytes
(red) indicated double-labeled cells in the onset and in the relapse phases
(panels d–f and j–l), while no staining was observed in the remission phase
or in controls (panels a–c and g–i). (B) Localization of the double positive
staining was restricted to white matter and to the granular layer of the
cerebellum; in the onset and relapse phases of the disease. None or few
cells were found in the cerebellum molecular layer. Mo, molecular layer; Gr,
granular layer; WM, white mater; n.d., not found. Data represent mean ± SE.
Scale bars, 100μm.
We have previously analyzed the CP transcriptome in the
context of the interplay between the periphery and the brain
in response to acute and repeated peripheral inflammation
(Marques et al., 2009a,b). Interestingly, the CP response dif-
fered depending on the stimulus. Overall, the CP transcriptome
changes appeared to be more pronounced in response to a tran-
sient and acute stimulation than during continuous (chronic)
stimulation, in which there seemed to be an adaptation of the
response. Portraying this, the highest observed fold changes we
observed in the present study were in the order of 3-fold mag-
nitude, indicating that EAE induction triggers a blunted CP
response more akin to that observed upon repeated peripheral
inflammation (3–4 fold) (Marques et al., 2009b) than after an
acute inflammatory challenge (up to 50-fold) (Marques et al.,
2009a). Furthermore, specifically for Lcn2 (here the highest up-
regulated gene), previous work showed that in the presence of
an acute stimulus, changes were restricted to CP epithelial cells
(Marques et al., 2008), when compared to a response by the
CP stromal cells in the presence of a chronic stimulus in which
no epithelial cells displayed LCN2 staining. Here, the LCN2 cell
expression pattern appeared again to parallel that of the chronic
model since LCN2 was found expressed by neutrophils, a stro-
mal cell population known to extensively infiltrate the brain in
the acute phase of EAE mice model and also in MS patients (Wu
et al., 2010; Naegele et al., 2012), and in astrocytes, but not in CP
epithelial cells. The relevance of LCN2 in EAE is further strength-
ened by the observation that the gene and the protein are also
increased in the spinal cord, and that the severity of the symp-
toms are higher in Lcn2-null mice, as recently described (Berard
et al., 2012).
Lipocalin 2 was first described as an acute phase protein
involved in the innate immunity given its ability to bind bacterial
siderophores (Flo et al., 2004). More recently, the identification
of mammalian siderophores (Devireddy et al., 2010) suggested
a novel function for LCN2 in iron homeostasis, as a protein
able to deliver iron to cells by a transferin-independent mecha-
nism (Devireddy et al., 2005). Therefore, either through its ability
to modulate iron delivery or through mechanisms still to be
identified, the current evidence suggests additional functions for
LCN2.
Further insights into the role of LCN2 in MS can be gleaned
from our novel finding revealing the expression of LCN2 in brain
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FIGURE 6 | Natalizumab abrogates the expression of LCN2 and LCN2 is
increased in the CSF of MS patients. (A) After EAE induction animals were
injected intraperitoneally with natalizumab or IgG (control for the treatment)
1, 3, and 5 days after the appearance of clinical symptoms. Animals were
sacrificed at the onset phase for the analysis of LCN2. (B) Treatment
attenuated the disease clinical score. (C) CSF LCN2 levels were modulated
and normalized by natalizumab treatment. (D and E) LCN2 astrocytic labeling
was strongly reduced upon natalizumb treatment both in the white matter
and in the granular layer of the cerebellum. (F) LCN2 was detected in
5 out of 20 control samples; 1 out of 9 ON patients and in 12 out of 20
patients with MS. CSF levels were significantly higher in MS patients when
compared to the non-MS individuals. Data are representative of two
independent cohorts from Portugal and Denmark. Data represent mean ±
SE. CSF samples below the detection (0.5 ng/ml) were given the value of
0.5 ng/ml. Mo, molecular layer; Gr, granular layer; WM, white mater. Scale
bars, 100μm.
astrocytes of EAEmice, exclusively during the active phases of dis-
ease. Interestingly, Berard et al. (2012) have similarly described
LCN2 label in spinal cord astrocytes in EAE; but not in post-
mortem brain tissue from patients with MS; which may be
attributed to differences between humans and rodents, or to the
stage of the disease. Even though the participation of astrocytes
in MS has been poorly investigated, astrocytes have been shown
to have an active role in axonal-associated damage during the
early phases of murine EAE (Wang et al., 2005). Further under-
standing on whether LCN2 is a marker of activated astrocytes
alone, or represents a key mediator in the astrocytes involvement
in MS pathogenesis might have implications for the develop-
ment of neuroprotective therapeutic strategies, which deserves
further research. Also of relevance will be to investigate whether
the decrease in astrocytic LCN2 during the remission phase
results from apoptosis of reactive astrocytes (Lee et al., 2009)
or from a decreased inflammatory response due to the lower
number of infiltrating immune cells. Similarly, the lower num-
ber of astrocytes producing LCN2 upon treatment may relate
with natalizumab’s ability to diminish immune cell entry into
the brain.
LCN2 has been recently suggested to participate in the initia-
tion of inflammation and leukocyte migration into injured spinal
cord sites (Rathore et al., 2011) and, in the brain, as a promoter
of cell migration that occurs through chemokine up-regulation
(Lee et al., 2011). However, the observation that EAE Lcn2-null
mice have increased number of infiltrating immune cells in the
lesions, when compared to EAE wild-type mice (Berard et al.,
2012), questions the role of LCN2 in cell migration. LCN2 is also
known to modulate iron availability (Richardson, 2005), which is
of relevance since iron is necessary formyelinization. Importantly,
iron seems to accumulate in human MS brain lesions and also in
mice; in the latter, treatment with the iron chelator desferrioxam-
ine reduces clinical and pathologic signs of EAE (Pedchenko and
LeVine, 1998).
The results obtained in the murine model were translatable
into humans, which corroborated the relevance of the findings.
MS patients from two different cohorts presented increased CSF
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LCN2 levels. These observations are in line with the increased
LCN2 levels in the serum of relapsing-remitting MS patients rel-
ative to healthy controls (Berard et al., 2012). Here we showed
that LCN2 CSF levels of MS patients are increased in compari-
son with healthy controls and ON patients. These observations
in humans are also in line with two separate GEO database
entries on EAE/MS studies, where Lcn2 expression appears 50%
increased in post-mortem brains of MS patients (GDS2978) and
in spinal tissue from EAE animals (GDS510). Altogether, these
data support the inclusion of LCN2 CSF levels in the panel of
inflammatory MS markers to monitor therapy and disease pro-
gression. One important question that should be addressed in the
future is to evaluate whether LCN2 levels rise earlier than cur-
rent diagnostic markers of the disease. CSF analyses are often
performed as an aid to diagnosis of MS, especially in the early
presentations, since the presence of OCB doubles the risk of
developing MS after a first demyelinating event (Tintore et al.,
2008). However, many patients with positive OCB might never
develop the disease, particularly when the imaging studies are
less informative (Tintore et al., 2008). Finding of additional
biomarkers of disease, including in the CSF, is therefore of clin-
ical relevance so to identify patients that would benefit from
early treatment (Comi et al., 2000). Interestingly, five MS sam-
ples had no measurable CSF LCN2: of these, three also did not
present OCBs, and four corresponded to patients with longer
remission periods. In the present study we not only comparedMS
patients with controls, but also with ON patients. ON is often
seen as the debut symptom in MS and approximately 50% of
patients with ON convert into MS within 6 years (The Optic
Neuritis Study Group, 2008). However, when no white mat-
ter lesions are detected, the risk of ON patients to develop MS
in a 15-year period decreases, but is still higher than that of
controls. The ON patients in this study were at low risk of pro-
gressing to MS due to normal MRI or to the lack of OCB. The
follow-up of these individuals is crucial to determine whether the
absence of LCN2 expression found in most of them is a prognos-
tic marker for no progression into MS or, otherwise, whether the
presence of LCN2 in ON individuals correlates with conversion
into MS.
Here we identify LCN2 as a novel protein whose presence in
the CSF and expression in the brain parenchyma is unique to
the active phases in the EAE mice model. Additionally we found
that the astrocytic LCN2 expression was restricted to the regions
typically affected in MS patients. Since LCN2 CSF levels were
also found significantly elevated in MS patients the observations
support LCN2’s inclusion in the panel of MS CSF markers.
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